In the first, Amann et al., showed that blockade of the renin–angiotensin system in patients with type 2 diabetes was associated with a reduction in urinary MCP-1 levels as well as an improvement in renal function [72]. Here, CCL2 is linked to type 2 diabetes mellitus.